Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 28

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 28
---
 their holders, but rather merely represent the right to acquire shares of our Common Stock at a fixed price. Until holders of May 2025 Warrants and Pre-Funded Warrants acquire shares of our Common Stock upon exercise of the May 2025 Warrants and Pre-Funded Warrants, as applicable, holders of May 2025 Warrants and Pre-Funded Warrants will have no rights with respect to our shares of Common Stock underlying such May 2025 Warrants and Pre-Funded Warrants.

| 10 |

We are required to obtain Warrant Stockholder Approval prior to exercise of the May 2025 Warrants and until we are able to receive such approval the May 2025 Warrants will not be exercisable. In addition, the shares of Common Stock issuable upon the Anti-Dilution Adjustment have not been registered pursuant to this prospectus. If we are unable to obtain such approval the May 2025 Warrants will have no value.

We are required to obtain Warrant Stockholder Approval prior to the exercise of the May 2025 Warrants and until, and unless, we obtain the Warrant Stockholder Approval from our stockholders, the May 2025 Warrants will not be exercisable. While we intend to promptly seek stockholder approval of both the amendment to our certificate of incorporation to increase our number of authorized shares of Common Stock and the exercise of the May 2025 Warrants and the issuance of the shares of Common Stock upon such exercise, there is no guarantee that the Warrant Stockholder Approval will ever be obtained. If we are unable to obtain the Warrant Stockholder Approval, the May 2025 Warrants will have no value. In addition, we will incur substantial cost, and management will devote substantial time and attention, in attempting to obtain the Warrant Stockholder Approval. Furthermore, the shares of Common Stock issuable upon the Anti-Dilution Adjustment have not been registered and although we intend to register them after obtaining the Warrant Stockholder Approval, we cannot guarantee that they will be registered.

If we do not maintain a current and effective prospectus relating to the Common Stock issuable upon exercise of the May 2025 Warrants, public holders will only be able to exercise such May 2025 Warrants on a “ cashless basis.”

If we do not maintain a current and effective prospectus relating to the shares of Common Stock issuable upon exercise of the May 2025 Warrants at the time that holders wish to exercise such warrants, they will